Loading…
Loading…
The Tema Oncology ETF (CANC) is designed to strategically invest in companies well-positioned to capitalize on significant advancements within cancer-focused biotechnology and the broader healthcare sector.
Is CANC's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), a leader in institutional-quality and actively managed exchange-traded funds, has surpassed $5 billion in assets under management (AUM) three years since listing its first product with $5 million.1 Tema has grown AUM by more than $3 billion in the first five months of 2026,2 underscoring strong momentum and growing adoption from financial advisors and professional investors.
NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), a leader in institutional-quality and actively managed exchange-traded funds, today announced that the firm has surpassed $2 billion in assets under management. The milestone comes less than eight months after surpassing $1 billion, and less than three years after listing its first ETF with under $5 million in seed capital. Tema's recent growth has been led by three 2026 highlights: Institutional Adoption: More than 90% of Tema's AUM has been sourc.
Tema Oncology ETF receives a Hold rating due to inconsistent returns but it does currently have a high Quant Ranking in the healthcare subclass. CANC offers diversified exposure across market caps and geographies, focusing on firms combating cancer through biotech, pharmaceuticals, diagnostics, and devices. The ETF holds 55 stocks, with top 10 comprising 40% of the portfolio, balancing established giants and innovative small-caps.
NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), a leader in institutional-quality and actively managed exchange-traded funds, today announced the appointment of Steve Munroe as President. In this role, Mr. Munroe will partner with Tema Founder and CEO Maurits Pot and the firm's leadership team to accelerate the company's next phase of growth. He will oversee branding, marketing, distribution, and product strategy as Tema continues to gain momentum—raising more than $1 billion in net new assets o.
Thrivent Financial for Lutherans cut its holdings in shares of Tema Oncology ETF (NASDAQ: CANC) by 84.6% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 147,472 shares of the company's stock after selling 810,003 shares during the period. Thrivent Financial